Spravato Treatment - Search News

US FDA approves new nasal spray for depression treatment

Hosted on MSN · 10h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

PopSugar · 20h

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

GlobalData on MSN1d

J&J’s Spravato receives FDA label expansion for depression monotherapy

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

J&J's Spravato gets another lift with new FDA approval

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Global Health Watch: Key Updates and Challenges

This summary covers the latest health-related news, including FDA's approval of Spravato as a standalone depression treatment ...

Inquirer on MSN3d

Controlled drug Ketamine a lifeline for patients with severe depression in S’pore

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results